TQB2868
Phase 2Small molecule
TQB2868 is one of 65 small molecule programs targeting Pancreatic Neoplasm. It is currently in Phase 2.
2
Indications
5
Total Trials
3
Active Trials
64
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Blenoxane
Bristol-Myers SquibbPreclinical
Lexiscan
AstellasPreclinical
Voltaren
NovartisPreclinical
Zolymbus
AbbViePreclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Duragesic-100
CCephalon
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Spravato
WWim Janssens
Preclinical
TQB2868
CChia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Breast Cancer1 trial
Pancreatic Ductal Adenocarcinoma1 trial
Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
Recruiting·SShanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.·Phase 3·NCT07165951·566 enrolled
Advanced Malignant Tumors1 trial
Clinical Trial of TQB2868 Injection in Subjects With Advanced Malignant Tumors
Unknown status·CChia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.·Phase 1·NCT05198505·280 enrolled
Pancreatic Neoplasm1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TQB2868. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details